TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06772428: A Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment Alone for Adjuvant Therapy in Patients With High-risk Factor

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06772428 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06772428 Rescue Dossier →